Alpine Strawberry Arsenic Trioxide Atropa Belladon
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpine Strawberry Arsenic Trioxide Atropa Belladon
- Multi-Ingredient Combination (13 Components): Evaluation Incomplete — No TxGNN Repurposing Prediction Available
Multi-Ingredient Combination (13 Components): Evaluation Incomplete — No TxGNN Repurposing Prediction Available
One-Sentence Summary
This submission describes a 13-component mixture — containing botanical, mineral, and chemically hazardous ingredients such as Arsenic Trioxide, Atropa Belladonna, Mercuric Chloride, and Strychnos Nux-Vomica Seed — whose original therapeutic indication is not recorded and which is not marketed in the United States. The TxGNN model generated no repurposing predictions for this entry, and no US NDA was found. This case cannot be evaluated under the standard drug repurposing framework until the formulation identity and indication are clarified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Unknown — no regulatory record found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no prediction generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This submission is a multi-ingredient entry containing 13 distinct substances:
Alpine Strawberry · Arsenic Trioxide · Atropa Belladonna · Cajuput Oil · Capsicum · Cinchona Officinalis Bark · Frangula Purshiana Bark · Lycopodium Clavatum Spore · Mercuric Chloride · Nitric Acid · Phosphorus · Phytolacca Americana Root · Strychnos Nux-Vomica Seed
The TxGNN knowledge graph operates on single active pharmaceutical ingredients (APIs) mapped to DrugBank IDs. A compound mixture submitted as a single INN string cannot be resolved to a node in the knowledge graph, which explains why no predictions were returned. Additionally, no DrugBank ID was assigned (drugbank_id: null), confirming that the system was unable to identify a canonical drug entity.
The formulation profile is consistent with a homeopathic or traditional compound preparation, where multiple low-dose botanical and mineral ingredients are combined. Such preparations fall outside the TxGNN model’s training domain and cannot be assessed using the standard pipeline.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination as a unified formulation.
Literature Evidence
Currently no related literature available for this multi-ingredient combination as a unified formulation.
US Market Information
No US marketing authorizations found.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No records found in US regulatory database |
Safety Considerations
This formulation contains multiple high-risk substances that warrant immediate safety review before any further evaluation.
- Arsenic Trioxide: An approved antineoplastic agent (used in acute promyelocytic leukaemia at therapeutic doses), but also a potent toxin at uncontrolled doses. Cardiotoxicity (QT prolongation), peripheral neuropathy, and myelosuppression are known risks.
- Mercuric Chloride: A highly toxic inorganic mercury compound; nephrotoxic and corrosive. Not approved for systemic use.
- Nitric Acid: A corrosive mineral acid; no established therapeutic use as a systemic agent.
- Atropa Belladonna: Contains atropine and scopolamine (anticholinergic alkaloids); narrow therapeutic index, significant overdose risk.
- Strychnos Nux-Vomica Seed: Source of strychnine; a potent neurotoxin causing tetanic convulsions.
- Phosphorus: Elemental phosphorus is hepatotoxic and nephrotoxic.
The co-presence of multiple toxic substances in a single preparation raises serious safety concerns that cannot be assessed without knowing the dose, form (homeopathic dilution vs. full concentration), and regulatory classification of the finished product.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline requires a single, DrugBank-resolvable active ingredient to generate repurposing predictions. This entry was submitted as a 13-component mixture with no assigned DrugBank ID, no original indication, no US regulatory approval, and no safety data — none of the minimum requirements for evaluation are met. Additionally, the presence of Arsenic Trioxide, Mercuric Chloride, and Strychnine in the same formulation triggers a mandatory safety review before any further analysis.
To proceed, the following is needed:
- Formulation clarification: Confirm whether this is a homeopathic product (with ultra-dilute ingredients per pharmacopoeial standards) or a conventional multi-herb/mineral preparation; the regulatory and safety implications differ fundamentally.
- Target API identification: If the intent is to evaluate a single active ingredient (e.g., Arsenic Trioxide for oncology repurposing), resubmit that ingredient individually with its DrugBank ID (DB01169).
- Regulatory status verification: Confirm the country of origin and applicable regulatory framework; homeopathic OTC products may be registered under different pathways (e.g., FDA OTC monograph, homeopathic drug ANDA).
- Safety data for component substances: Obtain package insert or equivalent toxicology data for each ingredient, particularly the four high-risk compounds identified above.
- Dose and concentration data: Homeopathic preparations (e.g., 6C, 30C dilutions) carry different risk profiles than conventional concentrations; this information is essential before any safety conclusion can be drawn.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.